RZLT Insider Trading
Insider Ownership Percentage: 18.39%
Insider Buying (Last 12 Months): $425,506.35
Insider Selling (Last 12 Months): $0.00
Rezolute Share Price & Price History
Current Price: $3.85
Price Change: ▼ Price Decrease of -0.02 (-0.52%)
As of 03/7/2025 05:00 PM ET
Rezolute Insider Trading History
Rezolute Institutional Trading History
Data available starting January 2016
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Read More on Rezolute
Volume
299,823 shs
Average Volume
452,640 shs
Market Capitalization
$233.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
Who are the company insiders with the largest holdings of Rezolute?
Who are the major institutional investors of Rezolute?
Rezolute's top institutional shareholders include:
- Nantahala Capital Management LLC — 4.93%
- Adage Capital Partners GP L.L.C. — 4.36%
- Altium Capital Management LLC — 2.92%
- Affinity Asset Advisors LLC — 2.72%
- ADAR1 Capital Management LLC — 2.35%
- Sphera Funds Management LTD. — 2.01%
Learn More about top institutional investors of Rezolute stock.
Which institutional investors are selling Rezolute stock?
During the last quarter, RZLT stock was sold by these institutional investors:
- Marshall Wace LLP
- Schonfeld Strategic Advisors LLC
- Bank of America Corp DE
- ADAR1 Capital Management LLC
- Renaissance Technologies LLC
- Affinity Asset Advisors LLC
- Cubist Systematic Strategies LLC
- Sphera Funds Management LTD.
Which institutional investors are buying Rezolute stock?
In the previous quarter, RZLT stock was bought by institutional investors including:
- Adage Capital Partners GP L.L.C.
- Woodline Partners LP
- Susquehanna International Group LLP
- Walleye Capital LLC
- Nantahala Capital Management LLC
- Integral Health Asset Management LLC
- J. Goldman & Co LP
- Point72 Europe London LLP
During the last year, these company insiders have bought Rezolute stock:
- Daron Evans (CFO)
- Young-Jin Kim (Director)
- Wladimir Hogenhuis (Director)
- Brian Kenneth Roberts (Insider)
- Nevan C Elam (CEO)
Learn More investors buying Rezolute stock.